Developing robust antibody titers against weak or structurally difficult antigens remains a major preclinical bottleneck.
When standard adjuvants fall short, the VacciTag™ platform by preclinics GmbH offers a smarter molecular approach. By tapping into pre-existing tetanus immunity, it delivers high titers without harsh, toxic additives.
At preclinics Italia, we contribute to the custom antigen design and production required to drive these high-titer workflows.
- Adjuvant-free formulation with excellent tolerability
- Immediate cellular and humoral response after prime immunization
- Overcomes low immunogenicity for challenging targets
- Cost-efficient and highly scalable
How it works (the tetanus shortcut):
- Fusion: your target antigen is fused to our proprietary ImmunoTag (containing a tetanus-derived epitope).
- Recognition: pre-existing anti-tetanus antibodies in the host instantly recognize and bind the tag.
- Activation: this binding forms immune complexes that trigger rapid immune cell recruitment and robust antigen processing — delivering high antibody titers.
Flexible formulations: DNA/RNA, soluble proteins, live bacteria, or VLPs.
Ideal for: lowly immunogenic antigens, structurally complex targets, highly conserved mammalian proteins, transmembrane proteins, and low-abundance targets.
Planning an immunization study with a challenging target? We can help you integrate VacciTag™ into your specific animal model and workflow. Get in touch: info@preclinics.com